Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Revvity, Inc. is a global life sciences and diagnostics company that provides technologies, services, and solutions used in discovery, development, and delivery of therapies, as well as in diagnostics and applied markets. The company operates primarily across the life sciences, diagnostics, and applied genomics industries, serving pharmaceutical and biotechnology companies, academic and government research institutions, clinical laboratories, and healthcare providers. Its core revenue drivers include instruments, consumables, reagents, software, and related services that support research, drug development, and clinical testing workflows.
Revvity’s unique positioning lies in its integrated portfolio that spans research tools through clinical and applied diagnostic solutions, enabling customers to generate, analyze, and translate biological and genomic data at scale. The company traces its origins to PerkinElmer, Inc., founded in 1937, which historically operated across analytical instruments, diagnostics, and industrial markets. In 2023, following the divestiture of its applied, food, and enterprise services businesses, the company rebranded as Revvity, Inc. to reflect its strategic focus on life sciences and diagnostics.
Business Operations
Revvity generates revenue through two primary operating segments: Life Sciences and Diagnostics. The Life Sciences segment provides reagents, consumables, instruments, software, and services supporting drug discovery, translational research, and applied genomics, including cell and gene therapy research tools. The Diagnostics segment focuses on clinical diagnostics, including newborn screening, reproductive health, and infectious disease testing, supplying both instruments and assay kits to laboratories and public health systems.
Operations are conducted across domestic and international markets, with manufacturing, R&D, and commercial activities distributed globally. Revvity controls proprietary assay technologies, automation platforms, imaging systems, and bioinformatics software that support recurring consumables and services revenue. The company operates through multiple wholly owned subsidiaries and maintains commercial partnerships with pharmaceutical companies, academic institutions, and public health agencies to deploy its technologies at scale.
Strategic Position & Investments
Revvity’s strategic direction centers on driving growth in high-value life sciences and diagnostics markets with strong recurring revenue characteristics. Key initiatives include expanding its consumables and reagents portfolio, deepening customer integration through workflow-based solutions, and investing in advanced genomics, cell analysis, and automation technologies. The company has emphasized organic innovation alongside targeted acquisitions to enhance capabilities in applied genomics and clinical diagnostics.
Notable investments and acquisitions in recent years include BioLegend, Inc., which strengthened Revvity’s position in immunology and cell analysis reagents, and Horizon Discovery Group plc, which expanded gene editing and applied genomics offerings. Revvity also continues to invest in digital and software-enabled solutions that support data-driven research and diagnostics, aligning with emerging trends in precision medicine and decentralized testing.
Geographic Footprint
Revvity is headquartered in Waltham, Massachusetts, United States, and operates globally across North America, Europe, Asia-Pacific, and other international markets. The company maintains significant commercial and operational presence in major life sciences hubs, including the United States, Western Europe, China, Japan, and India. These regions collectively represent the majority of its revenue and customer base.
Internationally, Revvity supports customers through a network of manufacturing facilities, R&D centers, and sales organizations, enabling localized production, regulatory compliance, and customer support. Its technologies are widely used in both developed and emerging markets, particularly in public health screening programs and pharmaceutical research environments.
Leadership & Governance
Revvity is led by an executive team with deep experience in life sciences, diagnostics, and global operations, guided by a strategic vision focused on scientific impact, operational discipline, and long-term value creation. The leadership emphasizes innovation, customer-centric solutions, and disciplined capital allocation following the company’s portfolio transformation and rebranding.
Key executives include:
- Prahlad Singh – President and Chief Executive Officer
- David H. Fuller – Senior Vice President and Chief Financial Officer
- Kevin Willoe – Senior Vice President and President, Life Sciences
- Clive Brown – Senior Vice President and President, Diagnostics
- Meghan Fitzgerald – Senior Vice President and Chief Human Resources Officer
The company is governed by a board of directors that oversees strategy, risk management, and corporate governance in alignment with shareholder interests and regulatory requirements.